{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:36:24Z","timestamp":1774294584265,"version":"3.50.1"},"reference-count":145,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Fitness assessment in patients with acute myeloid leukemia (AML) is critical to deliver the right therapy to the right patient. Although several scoring systems are available to aid in determining fitness, the absence of validation studies has resulted in the lack of universally accepted assessment procedures. This limitation, combined with the increasing availability of novel agents expanding the spectrum of less-intensive options, has introduced additional complexity to the fitness assessment process. In this evolving context, fitness should reflect eligibility for a specific treatment among the several available, rather than a generic binary classification of eligibility for intensive chemotherapy. Moreover, the growing emphasis on patient-centered care, further highlights the importance of integrating quality of life, patient preferences, patient self-reported physical and social functioning status, social support, and early integration of palliative care into the assessment framework. A modern interpretation of fitness assessment should incorporate a comprehensive evaluation that extends beyond traditional clinical and biological disease characteristics. Thus, fitness assessment in patients with AML represents only 1 piece of a larger puzzle, encompassing the patient\u2019s overall capacity to sustain and benefit from a specific therapeutic program.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013744","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T21:54:31Z","timestamp":1738878871000},"page":"2207-2220","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-0553","authenticated-orcid":false,"given":"Adriano","family":"Venditti","sequence":"first","affiliation":[{"name":"1Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 Tor Vergata, Rome, Italy"},{"name":"2Department of Onco-Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-8121","authenticated-orcid":false,"given":"Raffaele","family":"Palmieri","sequence":"additional","affiliation":[{"name":"1Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 Tor Vergata, Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7297-4988","authenticated-orcid":false,"given":"Luca","family":"Maurillo","sequence":"additional","affiliation":[{"name":"2Department of Onco-Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-0548","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[{"name":"3Medizinische Klinik und Poliklinik 1, Medizinische Fakult\u00e4t und Universit\u00e4tsklinikum Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-457X","authenticated-orcid":false,"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"5Department of Hematology and Transplantology, Provincial Multispecialized Oncology and Trauma Center, Lodz, Poland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-8467","authenticated-orcid":false,"given":"David","family":"de Leeuw","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Amsterdam University Medical Center, Location Vrije University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-5166","authenticated-orcid":false,"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[{"name":"7Data Center and Health Outcomes Research Unit, Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto, Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-6049","authenticated-orcid":false,"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[{"name":"8Dipartimento delle \u201cMalattie oncologiche ed ematologiche,\u201d Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"}]},{"given":"Lok Lam","family":"Ngai","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Amsterdam University Medical Center, Location Vrije University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-0824","authenticated-orcid":false,"given":"Jesse","family":"Tettero","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Amsterdam University Medical Center, Location Vrije University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[{"name":"9Service H\u00e9matologie S\u00e9niors, H\u00f4pital Saint-Louis (Assistance Publique\u2013H\u00f4pitaux de Paris), Paris Cit\u00e9 University and INSERM U944, Paris, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-0928","authenticated-orcid":false,"given":"Antonio","family":"Almeida","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Hospital da Luz, Lisbon, Portugal and Faculdade de Medicina, Universidade Cat\u00f3lica Portuguesa, Lisbon, Portugal"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu, Berlin, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-8673","authenticated-orcid":false,"given":"Mike","family":"Dennis","sequence":"additional","affiliation":[{"name":"12Hematology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"13Servicio de Hematolog\u00eda, Hospital Cl\u00ednic of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}]},{"given":"Felicetto","family":"Ferrara","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Cardarelli Hospital, Naples, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[{"name":"16Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-1705","authenticated-orcid":false,"given":"Priyanka","family":"Mehta","sequence":"additional","affiliation":[{"name":"18Hematology, University Hospitals of Bristol and Weston National Health Service Trust, Bristol, United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"19Hematology Department, Hospital Universitario i Polit\u00e8cnico la Fe, Valencia, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"20Department of Medical Oncology, Bern University Hospital, University of Bern, Inselspital, Bern, Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"21Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[{"name":"22Divisione di Ematologia, Ematologia, Azienda Socio Sanitaria Territoriale degli Spedali Civili, Brescia, Italy"}]},{"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[{"name":"23Hematology, Guy\u2019s and St Thomas\u2019 National Health Service Foundation Trust, London, United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-0356","authenticated-orcid":false,"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[{"name":"24Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}]},{"given":"Reinhard","family":"Stauder","sequence":"additional","affiliation":[{"name":"25Department of Public Health, Health Services Research and Health Technology Assessment, University for Health Sciences, Medical Informatics and Technology Tirol, The Tyrolean Private University, Hall in Tirol, Austria"},{"name":"26Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7027-040X","authenticated-orcid":false,"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[{"name":"27Hematology, Institut Paoli-Calmettes, Marseille, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"28Translational Science and Therapeutics Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice","family":"Wang","sequence":"additional","affiliation":[{"name":"29Leukemia Service, Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY"}]},{"given":"Samantha","family":"Nier","sequence":"additional","affiliation":[{"name":"30Acute Leukemia Advocates Network, Bern, Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6119-8034","authenticated-orcid":false,"given":"Carolina Garcez","family":"Martins","sequence":"additional","affiliation":[{"name":"30Acute Leukemia Advocates Network, Bern, Switzerland"}]},{"given":"Gert","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Amsterdam University Medical Center, Location Vrije University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands"}]}],"member":"234","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"3","key":"2025051213215785800_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17474086.2023.2185603","article-title":"Assessing eligibility for treatment in acute myeloid leukemia in 2023","volume":"16","author":"Venditti","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"2025051213215785800_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26079","article-title":"Determination of fitness and therapeutic options in older patients with acute myeloid leukemia","volume":"96","author":"Cortes","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2025051213215785800_bib3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"issue":"33","key":"2025051213215785800_bib4","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025051213215785800_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"issue":"21","key":"2025051213215785800_bib6","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2025051213215785800_bib7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/cancers12010120","article-title":"Therapeutic choice in older patients with acute myeloid leukemia: a matter of fitness","volume":"12","author":"Palmieri","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"2025051213215785800_bib8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.2023022611","article-title":"Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action","volume":"143","author":"Bhatt","year":"2024","journal-title":"Blood"},{"issue":"7650","key":"2025051213215785800_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"2025051213215785800_bib10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"key":"2025051213215785800_bib11","article-title":"Delphi technique in health sciences: a map","volume":"8:457","author":"Niederberger","year":"2020","journal-title":"Front Public Health"},{"key":"2025051213215785800_bib12","author":"R Core Team","year":"2019"},{"issue":"9","key":"2025051213215785800_bib13","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2025051213215785800_bib14","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial","volume":"5","author":"Kadia","year":"2018","journal-title":"Lancet Haematol"},{"issue":"18","key":"2025051213215785800_bib15","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2025051213215785800_bib16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"22","key":"2025051213215785800_bib17","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2025051213215785800_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14656566.2018.1465562","article-title":"Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia","volume":"19","author":"Michaelis","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"2025051213215785800_bib19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22537","article-title":"Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia","volume":"109","author":"Etienne","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"2025051213215785800_bib20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Haematol"},{"issue":"35","key":"2025051213215785800_bib21","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.20.01392","article-title":"Accuracy of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm","volume":"38","author":"Palmieri","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025051213215785800_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"2025051213215785800_bib23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1532-5415.2011.03614.x","article-title":"The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"59","author":"Klepin","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"2025051213215785800_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy\u2014a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"issue":"2","key":"2025051213215785800_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2012.067892","article-title":"Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome","volume":"98","author":"Deschler","year":"2013","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2025051213215785800_bib26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2018-99-115974","article-title":"Validation of a frailty score predicting survival of elderly, non-fit AML patients receiving hypomethylating therapy: results of the decider trial","volume":"132","author":"Hupfer","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2025051213215785800_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3324\/haematol.2022.280802","article-title":"Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question","volume":"108","author":"Jaramillo","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"2025051213215785800_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2025051213215785800_bib29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2025051213215785800_bib30","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"26","key":"2025051213215785800_bib31","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025051213215785800_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jgo.2018.11.005","article-title":"Understanding patients\u2019 values and priorities in selecting cancer treatments: developing a therapy preference scale","volume":"10","author":"Bhatt","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"11","key":"2025051213215785800_bib33","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025051213215785800_bib34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1705042","article-title":"Comorbidity and beyond: pre-transplant clinical assessment","volume":"36","author":"Artz","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025051213215785800_bib35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbmt.2012.11.006","article-title":"Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients","volume":"19","author":"Muffly","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025051213215785800_bib36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","article-title":"Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant Research study","volume":"21","author":"Sorror","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025051213215785800_bib37","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"key":"2025051213215785800_bib38","doi-asserted-by":"crossref","first-page":"659595","DOI":"10.3389\/fimmu.2021.659595","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?","volume":"12","author":"Loke","year":"2021","journal-title":"Front Immunol"},{"key":"2025051213215785800_bib39","unstructured":"National Comprehensive Cancer Network\n          . NCCN clinical practice guidelines V2.2025 acute myeloid leukemia (age &gt;18 years). Accessed 19 February 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"issue":"9","key":"2025051213215785800_bib40","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41409-023-02027-y","article-title":"Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"58","author":"Maffini","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2025051213215785800_bib41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2025051213215785800_bib42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025051213215785800_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood-2019-127251","article-title":"Outcomes after stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax-based therapies","volume":"134","author":"Pratz","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2025051213215785800_bib44","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","article-title":"10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial","volume":"10","author":"L\u00fcbbert","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025051213215785800_bib45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2025051213215785800_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-022-00668-8","article-title":"Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia","volume":"12","author":"Pratz","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"2025051213215785800_bib47","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"2025051213215785800_bib48","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"2025051213215785800_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0889-8588(05)70287-2","article-title":"Acute myelogenous leukemia and aging. Clinical interactions","volume":"14","author":"Lancet","year":"2000","journal-title":"Hematol Oncol Clin N Am"},{"issue":"24","key":"2025051213215785800_bib50","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"2025051213215785800_bib51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jgo.2015.10.182","article-title":"Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML)","volume":"7","author":"Tawfik","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"2025051213215785800_bib52","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/j.clml.2019.04.012","article-title":"A retrospective study of comorbidities and complications in elderly acute myeloid leukemia patients in the United States","volume":"19","author":"Dhopeshwarkar","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2025051213215785800_bib53","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.3324\/haematol.2018.196691","article-title":"Acute myeloid leukemia in very old patients","volume":"103","author":"Lazarevic","year":"2018","journal-title":"Haematologica"},{"key":"2025051213215785800_bib54","author":"United Nations Department of Economic and Social Affairs","year":"2022"},{"issue":"2","key":"2025051213215785800_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MOH.0000000000000480","article-title":"Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia","volume":"26","author":"Zuckerman","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"2025051213215785800_bib56","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11912-022-01299-9","article-title":"Older patients with acute myeloid leukemia deserve individualized treatment","volume":"24","author":"de Leeuw","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"2025051213215785800_bib57","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. [published correction appears in Ann Hematol. 2021;100(7):1917-1918]","volume":"100","author":"Heuser","year":"2021","journal-title":"Ann Hematol"},{"issue":"16","key":"2025051213215785800_bib58","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2025051213215785800_bib59","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025051213215785800_bib60","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025051213215785800_bib61","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/S2352-3026(22)00167-3","article-title":"Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia","volume":"9","author":"Short","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025051213215785800_bib62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am J Hematol"},{"issue":"24","key":"2025051213215785800_bib63","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2025051213215785800_bib64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","article-title":"Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. [published correction appears in Ann Hematol. 2023;102(8):2299]","volume":"102","author":"Zeidan","year":"2023","journal-title":"Ann Hematol"},{"issue":"8","key":"2025051213215785800_bib65","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"2025051213215785800_bib66","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/bjh.18709","article-title":"Venetoclax plus \u20182 + 5\u2019 modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis","volume":"201","author":"Wang","year":"2023","journal-title":"Br J Haematol"},{"issue":"30","key":"2025051213215785800_bib67","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): A phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025051213215785800_bib68","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025051213215785800_bib69","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025051213215785800_bib70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41375-022-01745-4","article-title":"Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms","volume":"37","author":"Paras","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"2025051213215785800_bib71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2013.092072","article-title":"Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification","volume":"99","author":"Wetzler","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2025051213215785800_bib72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1200\/JCO.1994.12.3.601","article-title":"Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group","volume":"12","author":"Loprinzi","year":"1994","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025051213215785800_bib73","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.bjc.6601231","article-title":"Performance status score: do patients and their oncologists agree?","volume":"89","author":"Blagden","year":"2003","journal-title":"Br J Cancer"},{"issue":"11","key":"2025051213215785800_bib74","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1054\/bjoc.2001.2162","article-title":"Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer","volume":"85","author":"Ando","year":"2001","journal-title":"Br J Cancer"},{"issue":"10","key":"2025051213215785800_bib75","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/JTO.0b013e318186a272","article-title":"Should patient-rated performance status affect treatment decisions in advanced lung cancer?","volume":"3","author":"Dajczman","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2025051213215785800_bib76","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jpainsymman.2018.02.015","article-title":"Patient-reported functional status in outpatients with advanced cancer: correlation with physician-reported scores and survival","volume":"55","author":"Popovic","year":"2018","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"2025051213215785800_bib77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025051213215785800_bib78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11899-016-0348-8","article-title":"Definition of unfit for standard acute myeloid leukemia therapy","volume":"11","author":"Klepin","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"2025051213215785800_bib79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.17294\/2330-0698.1951","article-title":"Understanding quality of life in patients with acute leukemia, a global survey","volume":"10","author":"Pemberton-Whiteley","year":"2023","journal-title":"J Patient Cent Res Rev"},{"issue":"10","key":"2025051213215785800_bib80","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/cncr.21006","article-title":"Disease biology rather than age is the most important determinant of survival of patients &gt;60 years with acute myeloid leukemia treated with uniform intensive therapy","volume":"103","author":"Gupta","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"2025051213215785800_bib81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461","volume":"108","author":"Cancer and Leukemia Group B 8461","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2025051213215785800_bib82","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2025051213215785800_bib83","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2025051213215785800_bib84","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2025051213215785800_bib85","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2025051213215785800_bib86","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"D\u00f6hner","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2025051213215785800_bib87","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1080\/10428194.2017.1422864","article-title":"Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2025051213215785800_bib88","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"issue":"21","key":"2025051213215785800_bib89","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"2025051213215785800_bib90","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2025051213215785800_bib91","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/leu.2014.216","article-title":"Management of older or unfit patients with acute myeloid leukemia","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2025051213215785800_bib92","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"25","key":"2025051213215785800_bib93","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2025051213215785800_bib94","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2025051213215785800_bib95","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2025051213215785800_bib96","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","article-title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia","volume":"33","author":"Pollyea","year":"2019","journal-title":"Leukemia"},{"issue":"10393","key":"2025051213215785800_bib97","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"2025051213215785800_bib98","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2025051213215785800_bib99","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025051213215785800_bib100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients","volume":"113","author":"Sekeres","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2025051213215785800_bib101","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","article-title":"Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia","volume":"121","author":"Bertoli","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2025051213215785800_bib102","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?","volume":"136","author":"R\u00f6llig","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025051213215785800_bib103","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/cancers15010136","article-title":"Time for dynamic assessment of fitness in acute myeloid leukemia","volume":"15","author":"Palmieri","year":"2022","journal-title":"Cancers"},{"issue":"20","key":"2025051213215785800_bib104","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.3390\/cancers13205075","article-title":"Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021","volume":"13","author":"Urbino","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"2025051213215785800_bib105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/cancers11020224","article-title":"Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia","volume":"11","author":"Ferrara","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"2025051213215785800_bib106","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"26","key":"2025051213215785800_bib107","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2025051213215785800_bib108","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2025051213215785800_bib109","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11899-022-00680-6","article-title":"Progress and challenges in survivorship after acute myeloid leukemia in adults","volume":"17","author":"Granroth","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"2025051213215785800_bib110","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"2025051213215785800_bib111","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"issue":"4","key":"2025051213215785800_bib112","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2025051213215785800_bib113","doi-asserted-by":"crossref","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","article-title":"A review of treatment options employed in relapsed\/refractory AML","volume":"28","author":"Mohamed Jiffry","year":"2023","journal-title":"Hematology"},{"issue":"4","key":"2025051213215785800_bib114","doi-asserted-by":"crossref","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2025051213215785800_bib115","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","article-title":"An overview of targeted therapies in acute myeloid leukemia","volume":"7","author":"Turkalj","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"2025051213215785800_bib116","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.critrevonc.2009.06.003","article-title":"Associations of social networks with cancer mortality: a meta-analysis","volume":"75","author":"Pinquart","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"2025051213215785800_bib117","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood-2017-11-814327","article-title":"Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study","volume":"131","author":"\u00d8stg\u00e5rd","year":"2018","journal-title":"Blood"},{"issue":"13","key":"2025051213215785800_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6004\/jnccn.2021.7033","article-title":"Association of social support with overall survival and healthcare utilization in patients with aggressive hematologic malignancies","volume":"19","author":"Johnson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2025051213215785800_bib119","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/asheducation-2016.1.339","article-title":"Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction","volume":"2016","author":"Rao","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2025051213215785800_bib120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s12288-018-1048-4","article-title":"Caregiver burden in the patients of acute myeloblastic leukemia","volume":"35","author":"Grover","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"6","key":"2025051213215785800_bib121","doi-asserted-by":"crossref","first-page":"150954","DOI":"10.1016\/j.soncn.2019.150954","article-title":"Supporting family caregivers of adult and pediatric persons with leukemia","volume":"35","author":"Dionne-Odom","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"2025051213215785800_bib122","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/EDBK_200383","article-title":"Implementation of patient-reported outcomes in routine medical care","volume":"38","author":"Basch","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"2025051213215785800_bib123","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3322\/caac.21150","article-title":"Electronic patient-reported outcome systems in oncology clinical practice","volume":"62","author":"Bennett","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2025051213215785800_bib124","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"2025051213215785800_bib125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025051213215785800_bib126","first-page":"1","article-title":"Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. [published correction appears in J Natl Cancer Inst. 2018;110(4):436]","volume":"109","author":"Denis","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2025051213215785800_bib127","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrclinonc.2015.29","article-title":"Patient-reported outcomes as end points and outcome indicators in solid tumours","volume":"12","author":"Secord","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2025051213215785800_bib128","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025051213215785800_bib129","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/S1470-2045(19)30656-4","article-title":"Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review","volume":"20","author":"Mierzynska","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025051213215785800_bib130","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"15","key":"2025051213215785800_bib131","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(15)00206-5","article-title":"Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study","volume":"16","author":"Efficace","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025051213215785800_bib132","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jgo.2021.09.007","article-title":"Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia","volume":"13","author":"Peipert","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"2025051213215785800_bib133","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025051213215785800_bib134","first-page":"CD011129","article-title":"Early palliative care for adults with advanced cancer","volume":"6","author":"Haun","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2025051213215785800_bib135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"2025051213215785800_bib136","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jamaoncol.2019.3105","article-title":"Association of early palliative care use with survival and place of death among patients with advanced lung cancer receiving care in the Veterans Health Administration","volume":"5","author":"Sullivan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"2025051213215785800_bib137","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/bmjspcare-2020-002710","article-title":"Early palliative intervention: effects on patient care satisfaction in advanced cancer","volume":"12","author":"Mah","year":"2022","journal-title":"BMJ Support Palliat Care"},{"issue":"7","key":"2025051213215785800_bib138","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jama.2009.1198","article-title":"Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial","volume":"302","author":"Bakitas","year":"2009","journal-title":"JAMA"},{"issue":"9930","key":"2025051213215785800_bib139","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","article-title":"Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial","volume":"383","author":"Zimmermann","year":"2014","journal-title":"Lancet"},{"issue":"13","key":"2025051213215785800_bib140","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1200\/JCO.2014.58.6362","article-title":"Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial","volume":"33","author":"Bakitas","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025051213215785800_bib141","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jamaoncol.2015.5252","article-title":"Emergency department-initiated palliative care in advanced cancer: A randomized clinical trial","volume":"2","author":"Grudzen","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"2025051213215785800_bib142","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/cancers14030478","article-title":"Early palliative care in acute myeloid leukemia","volume":"14","author":"Potenza","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"2025051213215785800_bib143","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamaoncol.2020.6343","article-title":"Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial","volume":"7","author":"El-Jawahri","year":"2021","journal-title":"JAMA Oncol"},{"issue":"e1","key":"2025051213215785800_bib144","doi-asserted-by":"crossref","first-page":"e1111","DOI":"10.1136\/bmjspcare-2021-002898","article-title":"Early palliative\/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study","volume":"14","author":"Potenza","year":"2021","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"2025051213215785800_bib145","doi-asserted-by":"crossref","first-page":"101626","DOI":"10.1016\/j.jgo.2023.101626","article-title":"Treating acute myelogenous leukemia in patients aged 70 and above: recommendations from the International Society of Geriatric Oncology (SIOG)","volume":"15","author":"Extermann","year":"2024","journal-title":"J Geriatr Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2207\/2372173\/blooda_adv-2024-013744-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2207\/2372173\/blooda_adv-2024-013744-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T17:22:23Z","timestamp":1747070543000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/9\/2207\/535487\/Fitness-assessment-in-acute-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":145,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013744","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}